Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: Body mass index (BMI) has been associated with breast cancer outcomes. However, few studies used clinical trial settings where treatments and outcomes are consistently evaluated and documented. There are also limited data assessing how patient/disease characteristics and treatment may alter the BMI–breast cancer association. Methods: We evaluated 15,538 breast cancer participants from four NSABP protocols. B-34 studied early-stage breast cancer patients (N = 3,311); B-30 and B-38 included node-positive breast cancer patients (N = 5,265 and 4,860); and B-31 studied node-positive and HER2-positive breast cancer patients (N = 2,102). We used Cox proportional hazards regression to calculate adjusted hazards ratios (HR) for risk of death and recurrence, and conducted separate analyses by estrogen receptor (ER) status and treatment group. Results: In B-30, increased BMI was significantly related to survival. Compared with BMI < 25, HRs were 1.04 for BMI 25 to 29.9 and 1.18 for BMI ≥ 30 (P = 0.02). Separate analyses indicated the significant relationship was only in ER-positive disease (P = 0.002) and the subgroup treated with doxorubicin/cyclophosphamide (P = 0.005). There were no significant trends across BMI for the other three trials. Similar results were found for recurrence. Increased BMI was significantly related to recurrence in B-30 (P = 0.03); and the significant relationship was only in ER-positive breast cancers (P = 0.001). Recurrence was also significant among ER-positive disease in B-38 (P = 0.03). Conclusions: In our investigation, we did not find a consistent relationship between BMI at diagnosis and breast cancer recurrence or death. Impact: This work demonstrates that the heterogeneity of breast cancer between different breast cancer populations and the different therapies used to treat them may modify any association that exists between BMI and breast cancer outcome. Cancer Epidemiol Biomarkers Prev; 25(1); 51–59. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ogden, C. L., Yanovski, S. Z., Carroll, M. D., & Flegal, K. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.052 · Cited by 1,561
Cited by
Petrelli, F., Cortellini, A., Indini, A., Tomasello, G., Ghidini, M., Nigro, O., Salati, M., Dottorini, L., Iaculli, A., Varricchio, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.3520 · Cited by 530
Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities
Jiralerspong, S., & Goodwin, P. J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.4480 · Cited by 405
Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm?
Tommasi, C., Balsano, R., Corianò, M., Pellegrino, B., Saba, G., Bardanzellu, F., Denaro, N., Ramundo, M., Toma, I., Fusaro, A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237239 · Cited by 76
Body mass index and breast cancer survival: a Mendelian randomization analysis
Guo, Q., Burgess, S., Turman, C., Bolla, M. K., Wang, Q., Lush, M., Abraham, J., Aittomäki, K., Andrulis, I. L., Apicella, C., et al. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyx131 · Cited by 64
Metadata
- Authors
- Cecchini, R. S., Swain, S. M., Costantino, J. P., Rastogi, P., Jeong, J.-H., Anderson, S. J., Tang, G., Geyer, C. E., Lembersky, B. C., Romond, E. H., Paterson, A. H. G., & Wolmark, N.
- Venue
- Cancer Epidemiology, Biomarkers & Prevention
- Published
- 2016-01-01
- Volume
- 25
- Issue
- 1
- Pages
- 51-59
- ISSN
- 1055-9965 (ISSN-L)
- 1538-7755
- OpenAlex
- W2122236503
- Cited by
- 40
- References
- 1
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. https://app.cochat.ai/papers/10.1158/1055-9965.epi-15-0334-t
- The paper
- Cecchini, R. S., Swain, S. M., Costantino, J. P., Rastogi, P., Jeong, J.-H., Anderson, S. J., Tang, G., Geyer, C. E., Lembersky, B. C., Romond, E. H., Paterson, A. H. G., & Wolmark, N. (2016). Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-15-0334-t
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.